Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefuroxime Axetil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | PGR | P06401 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 7/20 | 0.76 |
| ▸ | CTDSP1 | Q9GZU7 | 3/20 | 0.76 |
| ▸ | POLB | P06746 | 2/20 | 0.76 |
| ▸ | PKM | P14618 | 2/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.50 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.50 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefuroxime Axetil SCHEMBL6859269 | 1.00 | ABCC4 (1.00) | ABCC4PDE4ATDP1HSD17B10NR1I2 | |
| Cefuroxime Axetil SCHEMBL7767287 | 1.00 | ABCC4 (1.00) | ABCC4PDE4ATDP1HSD17B10NR1I2 | |
| Cefuroxime Axetil SCHEMBL379336 | 1.00 | ABCC4 (1.00) | ABCC4PDE4ATDP1HSD17B10NR1I2 | |
| Cefuroxime Axetil SCHEMBL13575811 | 1.00 | ABCC4 (1.00) | ABCC4PDE4ATDP1HSD17B10NR1I2 | |
| Cefuroxime Axetil SCHEMBL721709 | 1.00 | ABCC4 (1.00) | ABCC4PDE4ATDP1HSD17B10NR1I2 | |
| Cefuroxime Axetil SCHEMBL10556419 | 1.00 | ABCC4 (1.00) | ABCC4PDE4ATDP1HSD17B10NR1I2 | |
| Cefuroxime Axetil SCHEMBL2221553 | 0.97 | ABCC4 (0.95) | ABCC4PDE4ATDP1HSD17B10NR1I2 | |
| Cefuroxime Axetil SCHEMBL18048098 | 0.97 | ABCC4 (0.95) | ABCC4PDE4ATDP1HSD17B10NR1I2 | |
| Cefuroxime Axetil SCHEMBL2322261 | 0.97 | ABCC4 (0.94) | ABCC4PDE4ATDP1HSD17B10NR1I2 | |
| Cefuroxime Axetil SCHEMBL2322632 | 0.92 | ABCC4 (0.84) | ABCC4PDE4ATDP1HSD17B10NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10695 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| US-20260098299-A1 | GENE EXPRESSION-BASED IDENTIFICATION OF EARLY LYME DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-09 | — | — | US | claimed |
| US-20260048013-A1 | PHARMACEUTICAL FORMULATION WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | CONSEJO SUPERIOR INVESTIGACION (ES) | 2026-02-19 | — | — | US | claimed |
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-4071477-B1 | COMPOSITIONS AND METHODS FOR DIAGNOSING LYME DISEASE AND FOR PREDICTING LYME DISEASE SPIROCHETE ELIMINATION AFTER TREATMENT | QIAGEN SCIENCES LLC (US) | 2026-01-21 | — | — | EP | claimed |
| EP-3452124-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-10-08 | — | — | EP | claimed |
| EP-3452123-B1 | HEMOSTATIC DEVICES AND METHODS OF USE | MEDTRONIC INC (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250271428-A1 | PEPTIDE-BASED BIOMARKERS AND RELATED ASPECTS FOR DISEASE DETECTION | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2025-08-28 | — | — | US | claimed |
| US-20250244340-A1 | DIAGNOSING AND TREATING A PATHOLOGICAL CONDITION OF THE INTESTINAL TRACT | MAGNOSTICS LIMITED (IE) | 2025-07-31 | — | — | US | claimed |
| US-12371429-B2 | Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof | RECREO PHARMACEUTICALS LLC (US) | 2025-07-29 | — | — | US | claimed |
| EP-0223365-B1 | CEFUROXIME AXETIL DRAGEE | GLAXO GROUP LIMITED (GB) | 1991-02-27 | — | — | EP | claimed |
| US-4994567-A | Purification by recovering from solution by roller drying | GALAXO GROUP LIMITED (GB) | 1991-02-19 | — | — | US | claimed |
| US-4897270-A | Coated tablet containing cefuroxime axetil | GLAXO GROUP LIMITED | 1990-01-30 | — | — | US | claimed |
| US-4865851-A | WITH WATER INSOLUBLE LIPID COATING TO MASK BITTER TASTE | GLAXO GROUP LIMITED (GB) | 1989-09-12 | — | — | US | claimed |
| US-4820833-A | PURIFICATION BY SPRAY DRYING PRECIPITATION, FREEZE DRYING; CEPHALOSPORINS | GLAXO GROUP LIMITED (GB) | 1989-04-11 | — | — | US | claimed |
| CN-88102851-A | METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION | — | 1988-12-21 | — | — | CN | claimed |
| EP-0107276-B1 | NOVEL FORM OF CEFUROXIME ESTER, PROCESS FOR ITS PREPARATION AND COMPOSITION CONTAINING IT | GLAXO GROUP LIMITED (GB) | 1987-10-07 | — | — | EP | claimed |
| EP-0223365-A2 | Cefuroxime axetil dragee | GLAXO GROUP LIMITED (GB) | 1987-05-27 | — | — | EP | claimed |
| US-4562181-A | INCREASED ABSORPTION VIA THE GASTROINTESTINAL TRACT, ALLOWING FOR ORAL OR RECTAL ADMINISTRATION | GLAXO GROUP LIMITED (GB) | 1985-12-31 | — | — | US | claimed |
| EP-0107276-A2 | Novel form of cefuroxime ester, process for its preparation and composition containing it | GLAXO GROUP LIMITED (GB) | 1984-05-02 | — | — | EP | claimed |